Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: StkProfit$ who wrote (11981)	7/8/1999 7:14:00 AM
From: sainte-beuve	Read Replies (1) \| Respond to of 52051

Mark- I believe it is ELN on the NYSE See my previous post. Dirk

To: StkProfit$ who wrote (11981)	7/8/1999 7:45:00 AM
From: flickerful	Read Replies (2) \| Respond to of 52051

DGL, Mark...re: Elan Corp. & Alzheimer's. New Study May Unlock Mystery of Alzheimer's Disease and Speed Search for Effective Treatment An immunization with the very peptide that initiates accumulation of amyloid plaques in the brains of people with Alzheimer's disease reduces existing plaques and prevents further plaques from developing in mouse models, according to a research study to be published in the July 8th issue of the journal Nature. "This is an exciting and encouraging study for the prevention and possible treatment of Alzheimer's disease," says Bill Thies, Ph.D., Alzheimer's Association vice president of medical and scientific affairs. "For many years, scientists have hypothesized that the presence of amyloid plaques causes cell death and leads to a decline in a person's cognitive functions. Scientists now have an opportunity to test this theory and begin unlocking the mystery behind this devastating disease." Researchers at Elan Corporation, plc. immunized a group of transgenic mice -- mice genetically engineered to develop Alzheimer's disease pathology similar to that which is seen in humans -- with a form of the beta amyloid peptide called AN-1792. The results of their study were based on two separate experiments. In the first experiment, the mice were immunized at an age well before they developed amyloid plaque and associated brain damage. After 13 months, the researchers compared the brains of the immunized mice to three control groups of mice that were left untreated or had been given either shots of a saline solution or a different plaque-associated protein (SAP). The group treated with AN-1792 showed virtually no detectable amyloid deposits in their brains or surrounding neuropathology. The three control groups showed no reduction in the progressive deposition of plaques. The researchers concluded that these results raise the possibility of immunization with AN-1792 as a prevention against Alzheimer's disease. In the second experiment discussed in the Nature paper, mature mice, which already exhibited substantial Alzheimer pathology, were treated with AN-1792 for a period of seven months. Researchers used similar controls as in the first experiment. They found the results demonstrated that the level of plaques and related neuropathology was both halted, and in fact, reduced in the treated mice -- suggesting that this treatment may clear plaques even after they have formed. "This is a novel technique that points us in a new direction toward an effective clinical intervention for the treatment of Alzheimer's disease," says Thies. "It is a very rich time for Alzheimer's disease research, and developments like these today are capable of changing the course of research tomorrow." July 7, 1999 HOME - alz.org